LncRNA ZEB2-AS1在卵巢癌组织中的表达水平及临床病理特征与预后的关系  

Expression of LncRNA ZEB2-AS1 in ovarian cancer and its relationships with clinicopathological features and prognosis

作　　者：刘玉瑰 刘皓 尚合江 刘丽霞 纪妹[3] LIU Yugui;LIU Hao;SHANG Hejiang;LIU Lixia;JI Mei(Department of Obstetrics and Gynecology;Clinical Laboratory, Hebi People's Hospital, Henan Hebi 458030,China;Zhengzhou University,Henan Zhengzhou 450006,China)

机构地区：[1]鹤壁市人民医院妇产科,河南鹤壁458030 [2]鹤壁市人民医院检验科,河南鹤壁458030 [3]郑州大学,河南郑州450006

出　　处：《现代肿瘤医学》2021年第1期111-115,共5页Journal of Modern Oncology

基　　金：河南省科技攻关项目(编号:172102310057)。

摘　　要：目的:探讨长链非编码核糖核酸(LncRNA)锌指E盒结合同源盒蛋白2-AS1(LncRNA ZEB2-AS1)在卵巢癌组织中的表达水平,并分析其与患者临床病理特征及预后的关系。方法:收集2015年3月至2016年3月本院收治的卵巢癌患者90例为卵巢癌组,同时选取同期于本院体检的健康志愿者52例为对照组。实时荧光定量聚合酶链反应(qRT-PCR)检测LncRNA ZEB2-AS1表达水平。收集患者临床病理资料,根据LncRNA ZEB2-AS1表达水平检测结果将其分为高表达组(52例)与低表达组(38例),分析其与患者临床病理特征关系。对卵巢癌患者随访3年,采用Kaplan-Meier法分析LncRNA ZEB2-AS1表达与患者预后关系。采用Cox比例风险模型分析影响卵巢癌患者预后的相关因素。结果:卵巢癌患者血清LncRNA ZEB2-AS1表达水平显著高于对照组(P <0.05);LncRNA ZEB2-AS1表达水平与卵巢癌患者是否发生淋巴结转移、FIGO分期、分化程度及CA125水平明显相关(P <0.05);Kaplan-Meier法分析显示LncRNA ZEB2-AS1高表达组患者3年无疾病进展生存率与总生存率分别为25.00%、46.88%,LncRNA ZEB2-AS1低表达组患者PFS与OS均显著低于低表达组(P <0.05);Cox多因素分析显示淋巴结转移、FIGO分期、LncRNA ZEB2-AS1表达均是影响卵巢癌患者预后的独立危险因素(P <0.05)。结论:卵巢癌患者血清LncRNA ZEB2-AS1表达水平明显升高,且与患者临床病理特征及预后密切相关,可能作为卵巢癌早期诊断的标记物及治疗靶点。Objective:To investigate the expression of long non-coding ribonucleic acid(LncRNA)zinc finger E-box binding homeobox protein 2-AS1(LncRNA ZEB2-AS1)in ovarian cancer,and to analyze its relationships with clinicopathological characteristics and prognosis.Methods:Ninety patients with ovarian cancer admitted to our hospital from March 2015 to March 2016 were selected as the ovarian cancer group,and fifty-two healthy volunteers were selected as the control group.Real-time fluorescence quantitative polymerase chain reaction(qRT-PCR)was used to detect the expression levels of LncRNA ZEB2-AS1.The clinicopathological data of the patients were collected.According to the results of LncRNA ZEB2-AS1 expression,patients were divided into high expression group(52 cases)and low expression group(38 cases).Its relationship with clinicopathological characteristics was analyzed.Patients with ovarian cancer were followed-up for 3 years.The relationship between the expression of LncRNA ZEB2-AS1 with the prognosis of patients was analyzed by Kaplan-Meier method.Cox proportional hazard model was used to analyze the prognostic factors of ovarian cancer patients.Results:The expression levels of serum LncRNA ZEB2-AS1 in patients with ovarian cancer were significantly higher than those in the control group(P<0.05).The expression level of LncRNA ZEB2-AS1 was significantly correlated with lymph node metastasis,FIGO staging,differentiation and CA125 level in patients with ovarian cancer(P<0.05).Kaplan-Meier analysis showed that PFS and OS were 25.00%and 46.88%respectively of patients in the LncRNA ZEB2-AS1 high expression group,while PFS and OS in the LncRNA ZEB2-AS1 high expression group were significantly lower than those in the low expression group(P<0.05).Cox multivariate analysis showed that lymph node metastasis,FIGO staging and LncRNA ZEB2-AS1 expression were independent risk factors affecting the prognosis of ovarian cancer patients(P<0.05).Conclusion:The expression of serum LncRNA ZEB2-AS1 in patients with ovarian cancer is significa

关 键 词：卵巢癌 长链非编码核糖核酸(LncRNA)锌指E盒结合同源盒蛋白2-AS1 临床病理特征 预后 

分 类 号：R737.31[医药卫生—肿瘤]